Industry Outlook
Dravet syndrome treatment accounted for a market value of US$ 288.2 Mn in 2021 and projected to grow at a CAGR of 11.7% during the forecast period from 2022 to 2030. The current treatment options available for Dravet syndrome target specifically the symptomatic relief associated with epileptic seizures. However, recent drug approvals for Dravet syndrome treatment has increased the overall market size and attracted attention of major pharmaceutical companies. In June 2020, Epidiolex (Cannabidiol) from GW Pharmaceuticals approved by USFDA specifically for Dravet syndrome. Epidiolex was followed by Fintepla (Earlier ZX008) owned by Zogenix is under approval process in the U.S. & Europe, this announcement soared shares of Zogenix by 20.5% in March 2021. Thus, overall target specific drugs are entering in the Dravet syndrome treatment horizon due to which its market growth expected to spurt from 2022 to 2030.Stiripentol and cannabidiol will assist the significant growth of Dravet syndrome treatment market throughout the forecast period
In August 2020, the U.S. Food and Drug Administration (FDA) had approved stiripentol brand named as Diacomit to treat seizures associated with Dravet syndrome. Stiripentol's market share is growing at significant rate post 2020 due to higher efficiency, safety and prolonged relief from seizures. In addition to that, cannabidiol brand named as Epidiolex manufactured by GW Research Ltd. approved in June 2020. Cannabidol is first FDA-approved drug that contains a purified drug substance derived from marijuana. Thus, overall environment of Dravet syndrome treatment market is growing significantly due to strong drug pipeline and recently approved drugs.North America dominated the overall global market especially due to recent drug approvals and developed diagnostic technology
In 2021, North America dominated the market and expected to maintain its dominance throughout the forecast period due to key market drivers such as rising awareness related to neurological disorders, increasing demand for target-specific drugs to treat Dravet syndrome, and high accessibility & adaptability for recently launched drugs. During the forecast period from 2021 to 2029, Asia Pacific expected to grow significantly throughout the forecast period due to increasing awareness related to Dravet syndrome coupled with developing diagnostic technologies in neurological disease area.The key market players involved in the Dravet syndrome treatment industry studied based on financial data, product portfolio, current press releases, and key market strategies. This report also covers attractive investment proposition analyzed based on exclusive geographical PESTEL analysis. Major companies included in the report are GW Pharmaceuticals Plc., Ovid Therapeutics, PTC Therapeutics, Inc., Epygenix Therapeutics, Inc., Zogenix, Inc., Takeda Pharmaceutical Company Ltd., Biocodex S.A., OPKO Health Inc., and Biscayne Neurotherapeutics, Inc. among others.
Historical & Forecast Period
This study report represents analysis of each segment from 2020 to 2030 considering 2021 as the base year. Compounded Annual Growth Rate (CAGR) for each of the respective segments estimated for the forecast period of 2022 to 2030.The current report comprises of quantitative market estimations for each micro market for every geographical region and qualitative market analysis such as micro and macro environment analysis, market trends, competitive intelligence, segment analysis, porters five force model, top winning strategies, top investment markets, emerging trends and technological analysis, case studies, strategic conclusions and recommendations and other key market insights.
Research Methodology
The complete research study was conducted in three phases, namely: secondary research, primary research, and expert panel review. key data point that enables the estimation of Dravet Syndrome Treatment market are as follows:- Research and development budgets of manufacturers and government spending
- Revenues of key companies in the market segment
- Number of end users and consumption volume, price and value.
- Geographical revenues generate by countries considered in the report
- Micro and macro environment factors that are currently influencing the Dravet Syndrome Treatment market and their expected impact during the forecast period.
Market Segmentation
Drugs
- Topiramate
- Levetiracetam
- Zonisamide
- Valproic Acid
- Clobazam
- Clonzepam
- Stiripentol
- Cannabidiol
Key questions answered in this report
- What are the key micro and macro environmental factors that are impacting the growth of Dravet Syndrome Treatment market?
- What are the key investment pockets with respect to product segments and geographies currently and during the forecast period?
- Estimated forecast and market projections up to 2030.
- Which segment accounts for the fastest CAGR during the forecast period?
- Which market segment holds a larger market share and why?
- Are low and middle-income economies investing in the Dravet Syndrome Treatment market?
- Which is the largest regional market for Dravet Syndrome Treatment market?
- What are the market trends and dynamics in emerging markets such as Asia Pacific, Latin America, and Middle East & Africa?
- Which are the key trends driving Dravet Syndrome Treatment market growth?
- Who are the key competitors and what are their key strategies to enhance their market presence in the Dravet Syndrome Treatment market worldwide?
This product will be delivered within 2 business days.
Table of Contents
1. Preface1.1. Report Description
1.1.1. Purpose of the Report
1.1.2. Target Audience
1.1.3. Key Offerings
1.2. Market Segmentation
1.3. Research Methodology
1.3.1. Phase I - Secondary Research
1.3.2. Phase II - Primary Research
1.3.3. Phase III - Expert Panel Review
1.3.4. Assumptions
1.3.5. Approach Adopted
2. Executive Summary
2.1. Market Snapshot: Global Dravet Syndrome Treatment Market
2.2. Global Dravet Syndrome Treatment Market, By Drugs, 2021 (US$ Million)
2.3. Global Dravet Syndrome Treatment Market, By Geography, 2021 (US$ Million)
2.4. Attractive Investment Proposition by Geography, 2021
3. Dravet Syndrome Treatment Market: Competitive Analysis
3.1. Market Positioning of Key Dravet Syndrome Treatment Market Vendors
3.2. Strategies Adopted by Dravet Syndrome Treatment Market Vendors
3.3. Key Industry Strategies
3.4. Tier Analysis 2021 Versus 2030
4. Dravet Syndrome Treatment Market: Macro Analysis & Market Dynamics
4.1. Introduction
4.2. Global Dravet Syndrome Treatment Market Value, 2020 - 2030, (US$ Million)
4.3. Market Dynamics
4.3.1. Market Drivers
4.3.2. Market Restraints
4.3.3. Key Challenges
4.3.4. Key Opportunities
4.4. Impact Analysis of Drivers and Restraints
4.5. See-Saw Analysis
5. Dravet Syndrome Treatment Market: By Drugs, 2020-2030, USD (Million)
5.1. Market Overview
5.2. Growth & Revenue Analysis: 2021 Versus 2030
5.3. Market Segmentation
5.3.1. Topiramate
5.3.2. Levetiracetam
5.3.3. Zonisamide
5.3.4. Valproic Acid
5.3.5. Clobazam
5.3.6. Clonzepam
5.3.7. Stiripentol
5.3.8. Cannabidiol
6. North America Dravet Syndrome Treatment Market, 2020-2030, USD (Million)
6.1. Market Overview
6.2. Dravet Syndrome Treatment Market: By Drugs, 2020-2030, USD (Million)
6.3.Dravet Syndrome Treatment Market: By Region, 2020-2030, USD (Million)
6.3.1.North America
6.3.1.1. U.S.
6.3.1.1.1. Dravet Syndrome Treatment Market: By Drugs, 2020-2030, USD (Million)
6.3.1.2. Canada
6.3.1.2.1. Dravet Syndrome Treatment Market: By Drugs, 2020-2030, USD (Million)
6.3.1.3. Rest of North America
6.3.1.3.1. Dravet Syndrome Treatment Market: By Drugs, 2020-2030, USD (Million)
7. UK and European Union Dravet Syndrome Treatment Market, 2020-2030, USD (Million)
7.1. Market Overview
7.2. Dravet Syndrome Treatment Market: By Drugs, 2020-2030, USD (Million)
7.3.Dravet Syndrome Treatment Market: By Region, 2020-2030, USD (Million)
7.3.1.UK and European Union
7.3.1.1. UK
7.3.1.1.1. Dravet Syndrome Treatment Market: By Drugs, 2020-2030, USD (Million)
7.3.1.2. Germany
7.3.1.2.1. Dravet Syndrome Treatment Market: By Drugs, 2020-2030, USD (Million)
7.3.1.3. Spain
7.3.1.3.1. Dravet Syndrome Treatment Market: By Drugs, 2020-2030, USD (Million)
7.3.1.4. Italy
7.3.1.4.1. Dravet Syndrome Treatment Market: By Drugs, 2020-2030, USD (Million)
7.3.1.5. France
7.3.1.5.1. Dravet Syndrome Treatment Market: By Drugs, 2020-2030, USD (Million)
7.3.1.6. Rest of Europe
7.3.1.6.1. Dravet Syndrome Treatment Market: By Drugs, 2020-2030, USD (Million)
8. Asia Pacific Dravet Syndrome Treatment Market, 2020-2030, USD (Million)
8.1. Market Overview
8.2. Dravet Syndrome Treatment Market: By Drugs, 2020-2030, USD (Million)
8.3.Dravet Syndrome Treatment Market: By Region, 2020-2030, USD (Million)
8.3.1.Asia Pacific
8.3.1.1. China
8.3.1.1.1. Dravet Syndrome Treatment Market: By Drugs, 2020-2030, USD (Million)
8.3.1.2. Japan
8.3.1.2.1. Dravet Syndrome Treatment Market: By Drugs, 2020-2030, USD (Million)
8.3.1.3. India
8.3.1.3.1. Dravet Syndrome Treatment Market: By Drugs, 2020-2030, USD (Million)
8.3.1.4. Australia
8.3.1.4.1. Dravet Syndrome Treatment Market: By Drugs, 2020-2030, USD (Million)
8.3.1.5. South Korea
8.3.1.5.1. Dravet Syndrome Treatment Market: By Drugs, 2020-2030, USD (Million)
8.3.1.6. Rest of Asia Pacific
8.3.1.6.1. Dravet Syndrome Treatment Market: By Drugs, 2020-2030, USD (Million)
9. Latin America Dravet Syndrome Treatment Market, 2020-2030, USD (Million)
9.1. Market Overview
9.2. Dravet Syndrome Treatment Market: By Drugs, 2020-2030, USD (Million)
9.3.Dravet Syndrome Treatment Market: By Region, 2020-2030, USD (Million)
9.3.1.Latin America
9.3.1.1. Brazil
9.3.1.1.1. Dravet Syndrome Treatment Market: By Drugs, 2020-2030, USD (Million)
9.3.1.2. Mexico
9.3.1.2.1. Dravet Syndrome Treatment Market: By Drugs, 2020-2030, USD (Million)
9.3.1.3. Rest of Latin America
9.3.1.3.1. Dravet Syndrome Treatment Market: By Drugs, 2020-2030, USD (Million)
10. Middle East and Africa Dravet Syndrome Treatment Market, 2020-2030, USD (Million)
10.1. Market Overview
10.2. Dravet Syndrome Treatment Market: By Drugs, 2020-2030, USD (Million)
10.3.Dravet Syndrome Treatment Market: By Region, 2020-2030, USD (Million)
10.3.1.Middle East and Africa
10.3.1.1. GCC
10.3.1.1.1. Dravet Syndrome Treatment Market: By Drugs, 2020-2030, USD (Million)
10.3.1.2. Africa
10.3.1.2.1. Dravet Syndrome Treatment Market: By Drugs, 2020-2030, USD (Million)
10.3.1.3. Rest of Middle East and Africa
10.3.1.3.1. Dravet Syndrome Treatment Market: By Drugs, 2020-2030, USD (Million)
11. Company Profile
11.1. GW Pharmaceuticals Plc.
11.1.1. Company Overview
11.1.2. Financial Performance
11.1.3. Product Portfolio
11.1.4. Strategic Initiatives
11.2. Ovid Therapeutics
11.2.1. Company Overview
11.2.2. Financial Performance
11.2.3. Product Portfolio
11.2.4. Strategic Initiatives
11.3. PTC Therapeutics, Inc.
11.3.1. Company Overview
11.3.2. Financial Performance
11.3.3. Product Portfolio
11.3.4. Strategic Initiatives
11.4. Epygenix Therapeutics, Inc.
11.4.1. Company Overview
11.4.2. Financial Performance
11.4.3. Product Portfolio
11.4.4. Strategic Initiatives
11.5. Zogenix, Inc.
11.5.1. Company Overview
11.5.2. Financial Performance
11.5.3. Product Portfolio
11.5.4. Strategic Initiatives
11.6. Takeda Pharmaceutical Company Ltd.
11.6.1. Company Overview
11.6.2. Financial Performance
11.6.3. Product Portfolio
11.6.4. Strategic Initiatives
11.7. Biocodex S.A.
11.7.1. Company Overview
11.7.2. Financial Performance
11.7.3. Product Portfolio
11.7.4. Strategic Initiatives
11.8. OPKO Health Inc.
11.8.1. Company Overview
11.8.2. Financial Performance
11.8.3. Product Portfolio
11.8.4. Strategic Initiatives
11.9. Biscayne Neurotherapeutics, Inc.
11.9.1. Company Overview
11.9.2. Financial Performance
11.9.3. Product Portfolio
11.9.4. Strategic Initiatives
11.10. Stoke Therapeutics
11.10.1. Company Overview
11.10.2. Financial Performance
11.10.3. Product Portfolio
11.10.4. Strategic Initiatives
11.11. Sage Therapeutics
11.11.1. Company Overview
11.11.2. Financial Performance
11.11.3. Product Portfolio
11.11.4. Strategic Initiatives
11.12. Xenon Pharmaceuticals
11.12.1. Company Overview
11.12.2. Financial Performance
11.12.3. Product Portfolio
11.12.4. Strategic Initiatives
List of Figures
Figure 1 Global Dravet Syndrome Treatment Market: Market Coverage
Figure 2 Research Methodology and Data Sources
Figure 3 Market Size Estimation - Top Down & Bottom-Up Approach
Figure 4 Global Dravet Syndrome Treatment Market: Quality Assurance
Figure 5 Global Dravet Syndrome Treatment Market, By Drugs, 2021
Figure 6 Global Dravet Syndrome Treatment Market, By Geography, 2021
Figure 7 Market Geographical Opportunity Matrix - Global Dravet Syndrome Treatment Market, 2021
Figure 8 Market Positioning of Key Dravet Syndrome Treatment Market Players, 2021
Figure 9 Global Dravet Syndrome Treatment Market - Tier Analysis - Percentage of Revenues by Tier Level, 2021 Versus 2030
Figure 10 Global Dravet Syndrome Treatment Market, By Drugs, 2021 Vs 2030, %
Figure 11 U.S. Dravet Syndrome Treatment Market (US$ Million), 2020 - 2030
Figure 12 Canada Dravet Syndrome Treatment Market (US$ Million), 2020 - 2030
Figure 13 Rest of North America Dravet Syndrome Treatment Market (US$ Million), 2020 - 2030
Figure 14 UK Dravet Syndrome Treatment Market (US$ Million), 2020 - 2030
Figure 15 Germany Dravet Syndrome Treatment Market (US$ Million), 2020 - 2030
Figure 16 Spain Dravet Syndrome Treatment Market (US$ Million), 2020 - 2030
Figure 17 Italy Dravet Syndrome Treatment Market (US$ Million), 2020 - 2030
Figure 18 France Dravet Syndrome Treatment Market (US$ Million), 2020 - 2030
Figure 19 Rest of Europe Dravet Syndrome Treatment Market (US$ Million), 2020 - 2030
Figure 20 China Dravet Syndrome Treatment Market (US$ Million), 2020 - 2030
Figure 21 Japan Dravet Syndrome Treatment Market (US$ Million), 2020 - 2030
Figure 22 India Dravet Syndrome Treatment Market (US$ Million), 2020 - 2030
Figure 23 Australia Dravet Syndrome Treatment Market (US$ Million), 2020 - 2030
Figure 24 South Korea Dravet Syndrome Treatment Market (US$ Million), 2020 - 2030
Figure 25 Rest of Asia Dravet Syndrome Treatment Market (US$ Million), 2020 - 2030
Figure 26 Brazil Dravet Syndrome Treatment Market (US$ Million), 2020 - 2030
Figure 27 Mexico Dravet Syndrome Treatment Market (US$ Million), 2020 - 2030
Figure 28 Rest of Latin America Dravet Syndrome Treatment Market (US$ Million), 2020 - 2030
Figure 29 GCC Dravet Syndrome Treatment Market (US$ Million), 2020 - 2030
Figure 30 Africa Dravet Syndrome Treatment Market (US$ Million), 2020 - 2030
Figure 31 Rest of Middle East and Africa Dravet Syndrome Treatment Market (US$ Million), 2020 - 2030
List of Tables
Table 1 Global Dravet Syndrome Treatment Market By Drugs, 2020-2030, USD (Million)
Table 2 North America Dravet Syndrome Treatment Market By Drugs, 2020-2030, USD (Million)
Table 3 U.S. Dravet Syndrome Treatment Market By Drugs, 2020-2030, USD (Million)
Table 4 Canada Dravet Syndrome Treatment Market By Drugs, 2020-2030, USD (Million)
Table 5 Rest of North America Dravet Syndrome Treatment Market By Drugs, 2020-2030, USD (Million)
Table 6 UK and European Union Dravet Syndrome Treatment Market By Drugs, 2020-2030, USD (Million)
Table 7 UK Dravet Syndrome Treatment Market By Drugs, 2020-2030, USD (Million)
Table 8 Germany Dravet Syndrome Treatment Market By Drugs, 2020-2030, USD (Million)
Table 9 Spain Dravet Syndrome Treatment Market By Drugs, 2020-2030, USD (Million)
Table 10 Italy Dravet Syndrome Treatment Market By Drugs, 2020-2030, USD (Million)
Table 11 France Dravet Syndrome Treatment Market By Drugs, 2020-2030, USD (Million)
Table 12 Rest of Europe Dravet Syndrome Treatment Market By Drugs, 2020-2030, USD (Million)
Table 13 Asia Dravet Syndrome Treatment Market By Drugs, 2020-2030, USD (Million)
Table 14 China Dravet Syndrome Treatment Market By Drugs, 2020-2030, USD (Million)
Table 15 Japan Dravet Syndrome Treatment Market By Drugs, 2020-2030, USD (Million)
Table 16 India Dravet Syndrome Treatment Market By Drugs, 2020-2030, USD (Million)
Table 17 Australia Dravet Syndrome Treatment Market By Drugs, 2020-2030, USD (Million)
Table 18 South Korea Dravet Syndrome Treatment Market By Drugs, 2020-2030, USD (Million)
Table 19 Latin America Dravet Syndrome Treatment Market By Drugs, 2020-2030, USD (Million)
Table 20 Brazil Dravet Syndrome Treatment Market By Drugs, 2020-2030, USD (Million)
Table 21 Mexico Dravet Syndrome Treatment Market By Drugs, 2020-2030, USD (Million)
Table 22 Rest of Latin America Dravet Syndrome Treatment Market By Drugs, 2020-2030, USD (Million)
Table 23 Middle East and Africa Dravet Syndrome Treatment Market By Drugs, 2020-2030, USD (Million)
Table 24 GCC Dravet Syndrome Treatment Market By Drugs, 2020-2030, USD (Million)
Table 25 Africa Dravet Syndrome Treatment Market By Drugs, 2020-2030, USD (Million)
Table 26 Rest of Middle East and Africa Dravet Syndrome Treatment Market By Drugs, 2020-2030, USD (Million)
Companies Mentioned
- GW Pharmaceuticals Plc
- Ovid Therapeutics
- PTC Therapeutics Inc.
- Epygenix Therapeutics Inc.
- Zogenix Inc.
- Takeda Pharmaceutical Company Ltd.
- Biocodex S.A.
- OPKO Health Inc.
- Biscayne Neurotherapeutics Inc.
